INGRESS is presenting a poster at ISPOR in Vienna!
Age-related macular degeneration (AMD) is a major cause of visual impairment in the developed world, for which anti-vascular endothelial growth factor (VEGF) therapy is an effective treatment. However, recent evidence shows, that anti-VEGF treatment is not as effective in the everyday clinical setting as in clinical trials. The objective of our study was to evaluate treatment preferences of patients with nAMD using a discrete choice experiment (DCE) technique and, specifically, assess the importance of different attributes describing real-world intravitreal injection treatment. Please refer to our poster for further details!